Related Articles
Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer
PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis
FABP4 knockdown suppresses inflammation, apoptosis and extracellular matrix degradation in IL-1β-induced chondrocytes by activating PPARγ to regulate the NF-κB signaling pathway
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports